482 related articles for article (PubMed ID: 29130994)
1. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression.
Huang F; Wan J; Hu W; Hao S
Cell Physiol Biochem; 2017; 44(1):240-254. PubMed ID: 29130994
[TBL] [Abstract][Full Text] [Related]
2. TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model.
Huang F; Wan J; Hao S; Deng X; Chen L; Ma L
Cancer Immunol Immunother; 2017 Oct; 66(10):1321-1331. PubMed ID: 28601924
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity of leukemia-derived exosomes via transfection with lentiviral vectors encoding costimulatory molecules.
Hu W; Huang F; Ning L; Hao J; Wan J; Hao S
Cell Oncol (Dordr); 2020 Oct; 43(5):889-900. PubMed ID: 32578140
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression.
Huang F; Li Z; Zhang W; Li J; Hao S
Cancer Immunol Immunother; 2022 Sep; 71(9):2197-2212. PubMed ID: 35092480
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Potential of Extracellular Vesicles Released by Genetically Modified Murine Colon Carcinoma Cells With Overexpression of Interleukin-12 and shRNA for TGF-β1.
Rossowska J; Anger N; Wegierek K; Szczygieł A; Mierzejewska J; Milczarek M; Szermer-Olearnik B; Pajtasz-Piasecka E
Front Immunol; 2019; 10():211. PubMed ID: 30814999
[TBL] [Abstract][Full Text] [Related]
6. A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4
Li J; Huang F; Jiang Y; Zhao J; Wan J; Hao S
Front Immunol; 2022; 13():1043484. PubMed ID: 36466863
[TBL] [Abstract][Full Text] [Related]
7. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
Conroy H; Galvin KC; Higgins SC; Mills KH
Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
[TBL] [Abstract][Full Text] [Related]
8. Exosomes with membrane-associated TGF-β1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction.
Yu L; Yang F; Jiang L; Chen Y; Wang K; Xu F; Wei Y; Cao X; Wang J; Cai Z
Eur J Immunol; 2013 Sep; 43(9):2461-72. PubMed ID: 23716181
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
11. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
13. Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity.
Li W; Mu D; Tian F; Hu Y; Jiang T; Han Y; Chen J; Han G; Li X
Mol Med Rep; 2013 Dec; 8(6):1876-82. PubMed ID: 24146068
[TBL] [Abstract][Full Text] [Related]
14. Role of Lymphocyte Subsets in the Immune Response to Primary B Cell-Derived Exosomes.
Saunderson SC; McLellan AD
J Immunol; 2017 Oct; 199(7):2225-2235. PubMed ID: 28842467
[TBL] [Abstract][Full Text] [Related]
15. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
17. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
[TBL] [Abstract][Full Text] [Related]
18. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
20. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
